摘要
目的:观察拉米夫定治疗活动性肝炎肝硬化的近期疗效。方法:观察组在基础护肝下加用拉米夫定(100mg/d)治疗。对照组仅基础护肝、对症,均治疗1年,观察治疗前后患者症状、体征、肝功能和乙肝病毒复制指标。结果:观察组症状、体征、肝功能显著改善,HBeAg、HBVDNA阴转率显著高于对照组。结论:拉米夫定治疗活动性肝炎肝硬化的近期疗效明显、安全,未见明显不良反应。
Objective： To observe Lamivudine＇ s recent healing effect of curing the active hepatitis and hepatocirrhosis. Methods ： To observe the treatment of 48 patients by using more Lamivudine （100mg/d） under the basic liver protection. All of the matched groups are only based on basic liver protection and all are cured for a year, then observe the patients＇ symptom, physical sign, liver function and virus duplicate index of hepatitis B before and after the treatment. Results： Observation groups＇ symptom, physical sign and liver functioo improved greatly. The negative conversion rates of HBeAg and HBVDNA are higher than matched groups. Conclusion： Lamivudine＇ s treatment of active hepatitis and hepatocirrhosis is very good, safe and no adverse reaction.
出处
《赣南医学院学报》
2009年第1期46-47,共2页
JOURNAL OF GANNAN MEDICAL UNIVERSITY
关键词
活动性肝炎
肝硬化
拉米夫定
the active hepatitis
hepatocirrhosis
Lamivudine
